# US 2008/0305101 A1 · Methods and Compositions Related to Clot Binding Compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0305101 A1
- Document ID: US20080305101A1
- Status: Published application
- Kind: A1
- Application number: 11/967,509
- Filed: 2007-12-31
- Published: 2008-12-11
- Earliest claimed: 2007-01-03
- Assignees: Sanford-Burnham Medical Research Institute
- Inventors: Erkki Ruoslahti; Dmitri Simberg
- Web page: https://patentgrep.com/patent/US20080305101A1

## CPC

- A61K 47/6911: {the form being a liposome}
- A61K 47/62: the modifying agent being a protein, peptide or polyamino acid
- A61K 47/6923: {the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb}
- A61K 47/6929: {the form being a nanoparticle, e.g. an immuno-nanoparticle}
- A61K 49/1863: {the organic macromolecular compound being a polysaccharide or derivative thereof, e.g. chitosan, chitin, cellulose, pectin, starch}
- A61K 49/1866: {the nanoparticle having a (super)(para)magnetic core coated or functionalised with a peptide, e.g. protein, polyamino acid}
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A61P 7/10: Antioedematous agents; Diuretics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- B82Y 5/00: Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- Y10T 428/2984: Microcapsule with fluid core [includes liposome]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- B82Y: SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- Y10T: TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION

## Abstract

Disclosed are compositions and methods related to clot binding compounds. The disclosed targeting is useful for treatment of cancer and other diseases and disorders.

## Claims

### Claim 1

A conjugate comprising a surface molecule and a plurality of clot binding compounds, wherein the clot binding compounds selectively bind to clotted plasma protein, wherein the conjugate causes clotting and amplifies the accumulation of the conjugate in tumors.

### Claim 2 (depends on 1)

The conjugate of claim 1, wherein the conjugate comprises a sufficient number and composition of clot binding compounds such that the conjugate causes clotting and amplifies the accumulation of the conjugate in tumors.

### Claim 3 (depends on 2)

The conjugate of claim 2, wherein sufficiency of the number and composition of clot binding compounds is determined by assessing clotting and amplification of the accumulation of the conjugate in tumors in a non-human animal.

### Claim 4 (depends on 1)

The conjugate of claim 1, wherein the conjugate comprises a sufficient density and composition of clot binding compounds such that the conjugate causes clotting and amplifies the accumulation of the conjugate in tumors.

### Claim 5 (depends on 4)

The conjugate of claim 4, wherein sufficiency of the density and composition of clot binding compounds is determined by assessing clotting and amplification of the accumulation of the conjugate in tumors in a non-human animal.

### Claim 6 (depends on 1)

The conjugate of claim 1, wherein a plurality of the clot binding compounds are each independently selected from an amino acid segment comprising the amino acid sequence REK, a fibrin-binding peptide, a clot binding antibody, and a clot binding small organic molecule.

### Claim 7 (depends on 1)

The conjugate of claim 1, wherein a plurality of the clot binding compounds each independently comprise an amino acid segment comprising the amino acid sequence REK.

### Claim 8 (depends on 7)

The conjugate of claim 7, wherein the amino acid segments are each independently selected from amino acid segments comprising the amino acid sequence CREKA (SEQ ID NO: 1) or a conservative variant thereof, amino acid segments comprising the amino acid sequence CREKA (SEQ ID NO:1), amino acid segments consisting of the amino acid sequence CREKA (SEQ ID NO:1), and amino acid segments consisting of the amino acid sequence REK.

### Claim 9 (depends on 7)

The conjugate of claim 7, wherein the amino acid segments each independently comprise the amino acid sequence CREKA (SEQ ID NO: 1) or a conservative variant thereof.

### Claim 10 (depends on 7)

The conjugate of claim 7, wherein the amino acid segments each independently comprise the amino acid sequence CREKA (SEQ ID NO:1).

### Claim 11 (depends on 7)

The conjugate of claim 7, wherein the amino acid segment consists of the amino acid sequence CREKA (SEQ ID NO:1).

### Claim 12 (depends on 7)

The conjugate of claim 7, wherein the amino acid segment consists of the amino acid sequence REK.

### Claim 13 (depends on 1)

The conjugate of claim 1, wherein a plurality of the clot binding compounds each comprise a fibrin-binding peptide.

### Claim 14 (depends on 13)

The conjugate of claim 13, wherein the fibrin-binding peptides are independently selected from the group consisting of fibrin binding peptides and fibrin-binding derivatives thereof.

### Claim 15 (depends on 1)

The conjugate of claim 1, wherein a plurality of the clot binding compounds each comprise a clot binding antibody.

### Claim 16 (depends on 1)

The conjugate of claim 1, wherein a plurality of the clot binding compounds each comprise a clot binding small organic molecule.

### Claim 17 (depends on 1)

The conjugate of claim 1, wherein the surface molecule is a nanoparticle.

### Claim 18 (depends on 1)

The conjugate of claim 1, wherein the surface molecule is an iron oxide nanoparticle.

### Claim 19 (depends on 1)

The conjugate of claim 1, wherein the surface molecule is an albumin nanoparticle.

### Claim 20 (depends on 1)

The conjugate of claim 1, wherein the surface molecule comprises a liposome.

### Claim 21 (depends on 1)

The conjugate of claim 1, wherein the surface molecule comprises a microparticle.

### Claim 22 (depends on 1)

The conjugate of claim 1, wherein the surface molecule comprises a fluorocarbon microbubble.

### Claim 23 (depends on 1)

The conjugate of claim 1, wherein the conjugate comprises at least 100 clot binding compounds.

### Claim 24 (depends on 1)

The conjugate of claim 1, wherein the conjugate comprises at least 1000 clot binding compounds.

### Claim 25 (depends on 1)

The conjugate of claim 1, wherein the conjugate comprises at least 10,000 clot binding compounds.

### Claim 26 (depends on 1)

The conjugate of claim 1 wherein the surface molecule is detectable.

### Claim 27 (depends on 1)

The conjugate of claim 1, wherein the surface molecule is a therapeutic agent.

### Claim 28 (depends on 27)

The conjugate of claim 27, wherein the therapeutic agent is Abraxane.

### Claim 29 (depends on 1)

The conjugate of claim 1, wherein the conjugate further comprises one or more moieties.

### Claim 30 (depends on 29)

The conjugate of claim 29, wherein the moieties are independently selected from the group consisting of an anti-angiogenic agent, a pro-angiogenic agent, a cancer chemotherapeutic agent, a cytotoxic agent, an anti-inflammatory agent, an anti-arthritic agent, a polypeptide, a nucleic acid molecule, a small molecule, a fluorophore, fluorescein, rhodamine, a radionuclide, indium-111, technetium-99, carbon-11, and carbon-13.

### Claim 31 (depends on 29)

The conjugate of claim 29, wherein at least one of the moieties is a therapeutic agent.

### Claim 32 (depends on 31)

The conjugate of claim 31, wherein the therapeutic agent is paclitaxel.

### Claim 33 (depends on 31)

The conjugate of claim 31, wherein the therapeutic agent is taxol.

### Claim 34 (depends on 29)

The conjugate of claims 29, wherein at least one of the moieties is a detectable agent.

### Claim 35 (depends on 1)

The conjugate of claim 1, wherein the conjugate selectively homes to clotted plasma protein.

### Claim 36 (depends on 1)

The conjugate of claim 1, wherein the conjugate selectively homes to tumor vasculature, wound sites, or both.

### Claim 37 (depends on 1)

A method comprising administering to a subject the conjugate of claim 1, wherein the conjugate selectively homes to clotted plasma protein, wherein the conjugate causes clotting and amplifies the accumulation of the conjugate at the site of the clotted plasma protein.

### Claim 38 (depends on 37)

The method of claim 37, wherein the conjugate selectively homes to tumor vasculature, wound sites, or both.

### Claim 39 (depends on 37)

The method of claim 37, wherein the conjugate has a therapeutic effect.

### Claim 40 (depends on 39)

The method of claim 39, wherein the therapeutic effect is a slowing in the increase of or a reduction of tumor burden.

### Claim 41 (depends on 39)

The method of claim 39, wherein the therapeutic effect is a slowing of the increase of or reduction of tumor size.

### Claim 42 (depends on 39)

The method of claim 39, wherein the therapeutic effect is a reduction or blocking of blood circulation in a tumor.

### Claim 43 (depends on 39)

The method of claim 39, wherein the therapeutic effect is a reduction or cessation of bleeding at a wound site.

### Claim 44 (depends on 39)

The method of claim 39, wherein the therapeutic effect is a decrease in the time for bleeding to stop at a wound site.

### Claim 45 (depends on 39)

The method of claim 39, wherein the therapeutic effect comprises a reduction in inflammation, an increase in speed of wound healing, reduction in amounts of scar tissue, decrease in pain, decrease in swelling, decrease in necrosis, or a combination.

### Claim 46 (depends on 37)

The method of claim 37, wherein the clotting has a therapeutic effect.

### Claim 47 (depends on 37)

The method of claim 37, wherein the subject has one or more sites to be targeted, wherein the conjugate homes to one or more of the sites to be targeted.

### Claim 48 (depends on 37)

The method of claim 37, wherein the subject has a tumor, wherein the conjugate has a therapeutic effect on the tumor.
